Skip to content

DMRA - Damora Therapeutics, Inc. - AlphaYou

Discover Compare Pricing

Sign in Sign up

Home Smart money Buy calls Analyze

Back to stock searchD

Damora Therapeutics, Inc.

DMRA · NASDAQ

Save to watchlist

Price is syncing

Reported smart-money activity for this stock is still below.

D

DMRADamora Therapeutics, Inc.

Overview

No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.

Key stats

Aug 20

52-wk high: $38.33
52-wk low: $2.45
Prev close: $20.98
Mkt cap: $2.00B
Beta: 1.48
P/B: 5.1x

Smart money

8 funds hold a position and insiders have been net selling.

Real smart money

Funds holding this stock

8 holders

Combined position$524.1M

VG
Viking Global
Andreas Halvorsen · Q2 2026 13F
$60.1M
position
BA
Balyasny

Earnings

Reported Aug 4, 2026

Earnings came in 2.6% below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K

Financials

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $2.0B

Valuation

P/B5.10

Quality

Operating margin0.0%
ROE

Technicals

Technicals

Price structure

No data yet

Technicals sync when verified market data is available. No sample data is shown.

Company

Symbol: DMRA
Exchange: NASDAQ
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Market cap: $2.00B
Beta: 1.48

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Research hubs
About
Editorial policy
Methodology
Source coverage
Corrections

Privacy
Terms
Refunds
Disclaimer

© 2026 AlphaYou. All rights reserved.Not financial advice. Do your own research. Informational data only; past performance does not predict future results.

Profit margin

+0.0%

Op margin

+0.0%

ROE

-99.7%

Dmitry Balyasny · Q2 2026 13F

$32.0M

position

MI

Millennium

Israel Englander · Q1 2026 13F

$12.2M

position

5 more holders

Lite opens all of them for $16.50/month, paid yearly.

Unlock all 5 holders

Coverage gaps for DMRA

No recent Congress trade
No recent market-voice mention

Earnings per share

-$0.39-2.6%

-$0.38 expected

Next report

What the street expects next

EPS expected

-$0.37

-$0.48 to -$0.29

Revenue expected

$0.00

6 analysts

-99.7%

ROA-21.6%

Growth

Beta1.48